OnKure Therapeutics Announces Oversubscribed $150 Million Private Placement to Advance Next-Generation PI3Ka Pan-Mutant Selective Inhibitor Candidates in Breast Cancer and Vascular Anomalies [Yahoo! Finance]
OnKure Therapeutics Announces Oversubscribed $150 Million Private Placement to Advance Next-Generation PI3Ka Pan-Mutant Selective Inhibitor Candidates in Breast Cancer and Vascular Anomalies
OnKure Therapeutics (OKUR) had its price target lowered by HC Wainwright from $34.00 to $27.00. They now have a "buy" rating on the stock.
OnKure Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results